.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,580,282

« Back to Dashboard

Claims for Patent: 8,580,282

Title:Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
Abstract: The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations.
Inventor(s): Kollar; Mark David (Fort Collins, CO)
Assignee: St. Renatus, LLC (Fort Collins, CO)
Application Number:13/262,704
Patent Claims: 1. A pharmaceutical composition comprising: a) 2.5-3.5% (w/v) tetracaine, or a pharmaceutically acceptable salt thereof; b) a vasoconstrictor; and c) a pharmaceutically acceptable carrier.

2. The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition is for intranasal administration.

3. The pharmaceutical composition according to claim 2, wherein said composition comprises about 3% (w/v) tetracaine.

4. The pharmaceutical composition according to claim 2, wherein said vasoconstrictor is selected from the group consisting of: indirect .alpha..sub.1-adrenergic agonists; calcium channel blockers; meperidine; imidazole drugs; .alpha..sub.2-adrenergic agonists; imidazoline (I.sub.1) ligands; direct .alpha..sub.2-adrenergic agonists; substance P blockers/reducers; I-menthol; icilin; glutamate receptor inhibitors; and pharmaceutically acceptable salts thereof.

5. The pharmaceutical composition according to claim 4, wherein said vasoconstrictor is oxymetazoline, or a pharmaceutically acceptable salt thereof.

6. The pharmaceutical composition according to claim 5, wherein said oxyrnetazoline is oxymetazoline salt.

7. The pharmaceutical composition according to claim 6, wherein said composition comprises about 0.01-1.0% (w/v) oxymetazoline HCl.

8. The pharmaceutical composition according to claim 7, wherein said composition comprises about 0.05% (w/v) oxymetazoline HCl.

9. The pharmaceutical composition according to claim 2, wherein said composition further comprises a preservative.

10. The pharmaceutical composition according to claim 9, wherein said preservative is selected from the list consisting of: sugar alcohols, ethanol, benzyl alcohol, isopropanol, cresol, chlorocresol, and phenol.

11. The pharmaceutical composition according to claim 10, wherein said preservative is benzyl alcohol.

12. The pharmaceutical composition according to claim 11, wherein said composition comprises about 0.5-2.0% (w/v) benzyl alcohol.

13. The pharmaceutical composition according to claim 12, wherein said composition comprises about 0.9% (w/v) benzyl alcohol.

14. The pharmaceutical composition according to claim 2, wherein said composition further comprises a viscosity enhancing agent.

15. The pharmaceutical composition according to claim 14, wherein said viscosity enhancing agent is selected from the list consisting of: methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose and smart hydrogel.

16. The pharmaceutical composition according to claim 15, wherein said viscosity enhancing agent is hydroxyethylcellulose.

17. The pharmaceutical composition according to claim 16, wherein said composition comprises about 0.01-1.0% (w/v) hydroxyethylcellulose.

18. The pharmaceutical composition according to claim 17, wherein said composition comprises about 0.05% (w/v) hydroxyethylcellulose.

19. The pharmaceutical composition according to claim 2, wherein said pharmaceutically acceptable carrier is water, sugar alcohol, or alcohol (e.g., ethanol).

20. The pharmaceutical composition according to claim 19, wherein said pharmaceutically acceptable carrier is water.

21. The pharmaceutical composition according to claim 2, wherein said composition has a pH of 4.0-6.5.

22. The pharmaceutical composition according to claim 2, wherein said composition has a pH of 5.5.about.6.5.

23. The pharmaceutical composition according to claim 2, wherein said composition further comprises a preservative and a viscosity enhancing agent.

24. The pharmaceutical composition according to claim 2, wherein said composition comprises: TABLE-US-00004 Ingredient Formulation (% w/v) Tetracaine hydrochloride, USP 3.00 Oxymetazoline hydrochloride, USP 0.05 Citric acid anhydrous, USP 1.00 Sodium hydroxide, NF q.s. Benzyl alcohol, NT 0.90 Hydrochloric acid, NF q.s. Hydroxyethylcellulose, NF (5000 cps) 0.05 Purified water, USP q.s. to 100%.

25. A method for anesthetizing at least a portion of a patient's maxillary dental arch in a subject comprising selectively delivering into the nasal sinuses or rear of the nasal cavity of the subject a pharmaceutical composition according to claim 2, wherein at least a portion of the pharmaceutical composition is absorbed by nasal tissue located at the rear of the nasal cavity in the vicinity of the maxillary sinus.

26. The method according to claim 25, wherein at least a portion of the pharmaceutical composition is absorbed by nasal tissue located at the rear of the nasal cavity in the vicinity of the anterior dental plexus, extensions of the middle superior nerve, the posterior superior alveolar nerve, the nociceptors of the facial and buccal nerve, or the sphenopalatine (pterygopalatine) ganglion.

27. The method according to claim 26, wherein said pharmaceutical composition is delivered by nebulization or spraying.

28. The method according to claim 27, wherein said delivered spray is a stream or a plume.

29. The method according to claim 28, wherein the selective delivery into the nasal sinuses or rear of the nasal cavity comprises spraying said pharmaceutical composition 1-5 times into each of the nostrils of said subject.

30. The method according to claim 29, wherein said selective delivery into the nasal sinuses or rear of the nasal cavity comprises spraying said pharmaceutical composition 3 times into each of the nostrils of said subject.

31. The method according to claim 30, wherein each of the 3 sprays into each of the nostrils of said subject are separated by an interval of 4 minutes.

32. The method according to claim 26, wherein about 12-50 mg of tetracaine is delivered into the nasal sinuses or rear of the nasal cavity of said subject.

33. The method according to claim 32, wherein about 15.about.24 mg of tetracaine is delivered into the nasal sinuses or rear of the nasal cavity of said subject.

34. The method according to claim 26, wherein the particle size of said pharmaceutical composition that is delivered to the nasal sinuses or rear of the nasal cavity is about 5-50 microns.

35. The method according to claim 34, wherein the particle size of said pharmaceutical composition is about 10-20 microns.

36. The method according to claim 35, wherein the particle size of said pharmaceutical composition is about 10 microns or larger.

37. The method according to claim 36, wherein at least 85% of the particles of the pharmaceutical composition are about 10 microns or larger.

38. A method for anesthetizing at least a portion of a body part, organ, or tissue by delivering a pharmaceutical composition according to claim 2.

39. The method according to claim 38, wherein said tissue is epithelial tissue.

40. The method according to claim 39, wherein said tissue is mucosal tissue.

41. A device for delivery of a pharmaceutical composition, wherein said device comprises a pharmaceutical composition according to claim 2.

42. The device according to claim 41, wherein said device is for intranasal delivery of a pharmaceutical composition according to claim 2.

43. The device according to claim 42, wherein said device is capable of delivering said pharmaceutical composition to the nasal tissue located at the rear of the nasal cavity in the vicinity of the sphenopalatine (pterygopalatine) ganglion and maxillary nerve.

44. The device according to claim 42, wherein said device is pre-filled with a pharmaceutical composition according to claim 2.

45. The device according to any one of claims 42-44, wherein said device is a spray device.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc